Shares of Abbott Laboratories (ABT) are higher Wednesday after the company posted better-than-anticipated earnings for the third quarter. The medical device company reported earnings of $0.59 a share, exceeding analysts' forecasts by about $0.01. Revenue for the period was $5.3 billion, in line with Wall Street's expectations. For 2016, Abbott now sees earnings of between $2.19 and $2.21 a share versus its prior view for earnings of $2.14 to $2.24 a share. Analysts are projecting earnings of $2.20 a share for the full year.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.